A study has identified a new curcumin derivative, C210, that selectively reactivates the Epstein–Barr virus (EBV) lytic cycle by inhibiting heat shock protein 90 (HSP90), leading to cancer cell death. The traditional EBV lytic induction therapy has shortcomings like low efficacy and infectious virion production, which C210 addresses. C210 disrupts HSP90 function, inducing EBV lytic cycle without producing infectious virions. It enhances the EBV-reactivating effects of conventional drugs like SAHA. The study’s significance lies in developing novel lytic induction therapies for EBV-positive cancer treatment and suggests investigating C210’s efficacy and safety in animal models for future clinical trials.
Source link
Curcumin compound reactivates Epstein–Barr virus, offering safer cancer therapy
